TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30253790

Group type: COMPARATOR
Intervention: Universal prevention (Climate)
Number of subjects: 2190

Group type: COMPARATOR
Intervention: Combined universal and selective prevention (CAP)
Number of subjects: 2190

Group type: EXPERIMENTAL
Intervention: Control (Health education as usual)
Number of subjects: 2190
Study: 26955895

Group type: EXPERIMENTAL
Intervention: Mindfulness-based eating and stress management practices
Number of subjects: 194
Study: 24365774

Group type: EXPERIMENTAL
Intervention: Decreased LV compliance (measured as reduced LV end‐diastolic volume at an idealized LV end‐diastolic pressure of 20 mm Hg)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: RV remodeling (indicated by increased RV wall thickness)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Composite endpoint of cardiovascular hospitalization or death
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Hospitalization for heart failure (HF)
Number of subjects: 419
Study: 23069099

Group type: EXPERIMENTAL
Intervention: Echocardiography integrated with advanced cardiac life support (ACLS) protocol (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional ACLS protocol without echocardiography (Group B)
Number of subjects: 100
Study: 20108344

Group type: EXPERIMENTAL
Intervention: etaracizumab alone
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: etaracizumab + dacarbazine
Number of subjects: 112
Study: 17334144

Group type: EXPERIMENTAL
Intervention: Topical negative pressure
Number of subjects: 0
Study: 15728930

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 80 ppm for 72 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy for pulmonary tuberculosis
Number of subjects: 0
Study: 11849632

Group type: EXPERIMENTAL
Intervention: Contraceptive patch (Ortho Evra/Evra)
Number of subjects: 3330

Group type: COMPARATOR
Intervention: Oral contraceptive (Triphasil)
Number of subjects: 3330
Study: 10516746

Group type: EXPERIMENTAL
Intervention: Induction treatment (698 patients)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Induction treatment in patients >/=60 years
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Induction treatment in patients <60 years
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Period of diagnosis (1980-84/85-89/90-95)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Conventional combined chemotherapy in patients >/=60 years
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: No significant change in DFS and CR durations
Number of subjects: 784
Study: 8592718

Group type: EXPERIMENTAL
Intervention: Physical therapy (PT) referral
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Physical therapy implementation within 1 month of back injury
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Female gender and specific diagnosis
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Timing of physical therapy
Number of subjects: 2147
Study: 2013419

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily with NSAID treatment
Number of subjects: 190

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily without NSAID treatment
Number of subjects: 190
Study: 7036300

Group type: EXPERIMENTAL
Intervention: Maintenance BCG therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: No other treatment (Control)
Number of subjects: 93
Study: 30716200

Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy (2L CT)
Number of subjects: 144
Study: 28598730

Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Balanced-framed message
Number of subjects: 552
Study: 27085870

Group type: EXPERIMENTAL
Intervention: Zolpidem (12.5 mg at 2300) and Nabilone (3 mg at 0900 and 1800)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Zolpidem (12.5 mg at 2300)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 23815763

Group type: EXPERIMENTAL
Intervention: Weight-control intervention
Number of subjects: 30
Study: 22453547

Group type: EXPERIMENTAL
Intervention: 7.5% CO(2) inhalation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal/medical air (control)
Number of subjects: 23
Study: 19814838

Group type: EXPERIMENTAL
Intervention: Milk supplementation (2 years)
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Higher protein intake (55.9‐61.0 g/d on average)
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Protein from animal foods (particularly meat)
Number of subjects: 757
Study: 17645791

Group type: EXPERIMENTAL
Intervention: ICU follow-up programme with clinic appointments at 2-3 and 9 months after ICU discharge
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard in-hospital follow-up
Number of subjects: 270
Study: 16176401

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 196

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 196
Study: 12032194

Group type: EXPERIMENTAL
Intervention: High-flux haemodialysis
Number of subjects: 74
Study: 10409598

Group type: EXPERIMENTAL
Intervention: High-hormone phase (progesterone/estrogen)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-hormone phase (placebo)
Number of subjects: 8
Study: 7672489

Group type: EXPERIMENTAL
Intervention: Intranasal insulin therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Subcutaneous fast‐acting insulin
Number of subjects: 31
Study: 2205907

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 7043728

Group type: EXPERIMENTAL
Intervention: Diflunisal 1 g daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen 750 mg daily
Number of subjects: 0
Study: 31955711

Group type: EXPERIMENTAL
Intervention: PCA algorithms based on Krylov subspace and randomized singular value decomposition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing fast and memory-efficient PCA algorithms
Number of subjects: 0
Study: 30471973

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthwash
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29096671

Group type: EXPERIMENTAL
Intervention: Reactive focal drug administration (RFDA) using dihydroartemisinin‐piperaquine (DHAP)
Number of subjects: 4800

Group type: COMPARATOR
Intervention: Reactive focal test and treat (RFTAT) using artemether‐lumefantrine (AL)
Number of subjects: 4800
Study: 26065506

Group type: EXPERIMENTAL
Intervention: 1% chloramphenicol eye ointment
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2.5% povidone-iodine ophthalmic solution
Number of subjects: 60
Study: 23521128

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: 2‐CdA (cladribine)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: IT therapy responses
Number of subjects: 777
Study: 20646083

Group type: EXPERIMENTAL
Intervention: 350 mg of Wheat Extract Oil (WEO)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: WEO
Number of subjects: 51
Study: 18821119

Group type: EXPERIMENTAL
Intervention: 1% pramoxine hydrochloride lotion applied twice daily for 4 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control lotion
Number of subjects: 28
Study: 17892995

Group type: EXPERIMENTAL
Intervention: Cangrelor with half-dose t-PA
Number of subjects: 92

Group type: COMPARATOR
Intervention: Full-dose t-PA
Number of subjects: 92

Group type: COMPARATOR
Intervention: Cangrelor alone
Number of subjects: 92
Study: 17113442

Group type: EXPERIMENTAL
Intervention: 25 mg prednisolone intramuscularly immediately after surgery
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 25 mg prednisolone and diclofenac intramuscularly immediately after surgery
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sterile saline solution (control group)
Number of subjects: 45
Study: 15604833

Group type: EXPERIMENTAL
Intervention: Angioplasty and stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 0
Study: 11110934

Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy (RT)
Number of subjects: 12
Study: 8958363

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg orally daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1526735

Group type: EXPERIMENTAL
Intervention: Intravenous epinephrine infusion (1 microgram/hr)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study: 3915865

Group type: EXPERIMENTAL
Intervention: Proximate staple closure
Number of subjects: 57

Group type: COMPARATOR
Intervention: Suture closure (3/0 Prolene)
Number of subjects: 57
Study: 30108104

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab (FOLFIRI+Cetux)
Number of subjects: 340

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab (FOLFIRI+Beva)
Number of subjects: 340
Study: 28836054

Group type: EXPERIMENTAL
Intervention: Imatinib therapy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: ABCB1 polymorphisms study
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Haplotype analysis
Number of subjects: 69
Study: 25882384

Group type: EXPERIMENTAL
Intervention: Combination training (AT/RT)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Resistance training (RT)
Number of subjects: 196
Study: 23792286

Group type: EXPERIMENTAL
Intervention: Sustained painful proximal gastric balloon distension (PAIN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No distension (NO PAIN)
Number of subjects: 20
Study: 21784436

Group type: EXPERIMENTAL
Intervention: Nutritional support and earlier SCPC
Number of subjects: 230
Study: 19317379

Group type: EXPERIMENTAL
Intervention: Ramelteon, 8 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Zolpidem, 10 mg (positive control)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 18210981

Group type: EXPERIMENTAL
Intervention: Clinical equipoise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miller and Weijer's defense of clinical equipoise
Number of subjects: 0
Study: 15554771

Group type: EXPERIMENTAL
Intervention: Vitamin B6 600 mg/day b.i.d. for 5 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11672449

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy with transdermal oestradiol (50 microg/24 h patch or 1 mg/day gel) combined with oral dihydrogesterone (10 mg/day for 12 days/month, days 19-30).
Number of subjects: 22
Study: 9926031

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychological treatments
Number of subjects: 0
Study: 8161382

Group type: COMPARATOR
Intervention: Dihydroergotamine alone (N=177)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine with concomitant antiemetic (N=133)
Number of subjects: 311
Study: 3364231

Group type: EXPERIMENTAL
Intervention: Self-monitoring group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No self-monitoring control group
Number of subjects: 0
Study: 29804377

Group type: EXPERIMENTAL
Intervention: ETV monotherapy
Number of subjects: 580

Group type: COMPARATOR
Intervention: LAM and ADV combination therapy
Number of subjects: 580
Study: 28044367

Group type: EXPERIMENTAL
Intervention: 1% anthralin ointment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated side of the scalp (control)
Number of subjects: 30
Study: 25280988

Group type: EXPERIMENTAL
Intervention: Customized cushion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional cushion
Number of subjects: 40
Study: 23715641

Group type: EXPERIMENTAL
Intervention: Jitai tablets
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 21635609

Group type: EXPERIMENTAL
Intervention: Echocardiography (ECHO group)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Electrocardiography (ECG group)
Number of subjects: 156
Study: 17399814

Group type: EXPERIMENTAL
Intervention: 40 mg of simvastatin daily (n=40)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hypolipidaemic only diet (n=20)
Number of subjects: 60
Study: 17262124

Group type: EXPERIMENTAL
Intervention: Microwave disinfection (690 W for 6 min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chemical disinfection (immersion in 100 ppm chloride solution)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no disinfection)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mechanical polishing with microwave disinfection
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chemical polishing with chemical disinfection
Number of subjects: 18
Study: 15228176

Group type: EXPERIMENTAL
Intervention: Tutoring intervention with three 30-min sessions per week during 1st grade
Number of subjects: 581

Group type: COMPARATOR
Intervention: Control group (no tutoring)
Number of subjects: 581
Study: 10965722

Group type: EXPERIMENTAL
Intervention: BIS monitoring with propofol
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: BIS monitoring with sevoflurane
Number of subjects: 160

Group type: COMPARATOR
Intervention: BIS monitoring
Number of subjects: 160

Group type: COMPARATOR
Intervention: No BIS monitoring with propofol
Number of subjects: 160

Group type: COMPARATOR
Intervention: No BIS monitoring with sevoflurane
Number of subjects: 160
Study: 9200248

Group type: EXPERIMENTAL
Intervention: Immediate KR
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed KR
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Immediate KR + form estimation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Delayed KR + form estimation
Number of subjects: 60
Study: 1301847

Group type: EXPERIMENTAL
Intervention: Qi Xue granule (QXG)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Compound Salvia tablet (CST)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Plasma TXB2, 6‐keto‐PGF1 alpha (6 Kp) levels in normal subjects
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Plasma TXB2, 6‐keto‐PGF1 alpha (6 Kp) levels in AP cases
Number of subjects: 55
Study: 3927708

Group type: EXPERIMENTAL
Intervention: Aerosolized edetate sodium plus oral tetracycline twice daily for three months
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo aerosol plus oral tetracycline for three months
Number of subjects: 10
Study: 29721732

Group type: EXPERIMENTAL
Intervention: Topical diltiazem 2% ointment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 60
Study: 26496621

Group type: EXPERIMENTAL
Intervention: Enclomiphene citrate
Number of subjects: 2

Group type: COMPARATOR
Intervention: Testosterone gel (AndroGel® 1.62%)
Number of subjects: 2
Study: 24429320

Group type: EXPERIMENTAL
Intervention: Wood-burning clay cookstove
Number of subjects: 51

Group type: COMPARATOR
Intervention: Open fire (control)
Number of subjects: 51
Study: 23568851

Group type: EXPERIMENTAL
Intervention: 20 g of lecithin before surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20216353

Group type: EXPERIMENTAL
Intervention: Brief parenting intervention
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 18492315

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (Voluven); n = 32
Number of subjects: 65

Group type: COMPARATOR
Intervention: 3% gelatin (Plasmion); n = 33
Number of subjects: 65
Study: 16803913

Group type: EXPERIMENTAL
Intervention: Routine education group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intervention group (taught oral examination skills)
Number of subjects: 25

Group type: COMPARATOR
Intervention: E1 (initial oral examination)
Number of subjects: 25

Group type: COMPARATOR
Intervention: E2 (subsequent oral examination)
Number of subjects: 25
Study: 14650580

Group type: EXPERIMENTAL
Intervention: Gamadent toothpaste
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo toothpaste
Number of subjects: 28
Study: 10985707

Group type: EXPERIMENTAL
Intervention: Group C (isolated hypoperfusion)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Group D (congestion with hypoperfusion)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Group C and Group D
Number of subjects: 571
Study: 9117182

Group type: EXPERIMENTAL
Intervention: In-patient multidisciplinary team care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine out-patient care
Number of subjects: 80
Study: 8363078

Group type: EXPERIMENTAL
Intervention: Epidural clonidine
Number of subjects: 40
Study: 3487772

Group type: EXPERIMENTAL
Intervention: High-voltage electrical stimulation with ramp time of 1.0 sec.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-voltage electrical stimulation with ramp time of 3.5 sec.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-voltage electrical stimulation with ramp time of 5.0 sec.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as no ramp time or different stimulation method).
Number of subjects: 31
Study: 29244208

Group type: EXPERIMENTAL
Intervention: Joint gaming on a tablet
Number of subjects: 22

Group type: COMPARATOR
Intervention: Toy play
Number of subjects: 22

Group type: COMPARATOR
Intervention: Watching TV
Number of subjects: 22
Study: 26807050

Group type: EXPERIMENTAL
Intervention: DynaMed
Number of subjects: 28

Group type: COMPARATOR
Intervention: AccessMedicine
Number of subjects: 28
Study: 24752193

Group type: EXPERIMENTAL
Intervention: Modified Illinois change of direction test (MICODT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Illinois change of direction speed test (ICODT)
Number of subjects: 95
Study: 23688265

Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO) combined with deferiprone (DFP) at 75 mg/kg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Deferoxamine (DFO) monotherapy at 50-60 mg/kg 12-24 hr/day sc or iv 7 times weekly
Number of subjects: 20
Study: 21082587

Group type: EXPERIMENTAL
Intervention: Secure Tracks™
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard walker
Number of subjects: 30
Study: 18853561

Group type: EXPERIMENTAL
Intervention: Reduced image contrast in a video-based driving simulator
Number of subjects: 0
Study: 15701145

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 0
Study: 12714435

Group type: EXPERIMENTAL
Intervention: Seropositivity for P. gingivalis
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: High combined antibody response
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: High combined antibody response (adjusted for age and CHD risk factors)
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: Combined antibody response
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: Edentulousness
Number of subjects: 1163
Study: 12410369

Group type: EXPERIMENTAL
Intervention: Acupuncture (AP) treatments
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo acupuncture (AP) treatments
Number of subjects: 60
Study: 10765004

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of octreotide (50 microg every 6 hours) plus intravenous infusion of low-dose insulin (4 units per hour)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose insulin alone (4 units per hour)
Number of subjects: 0
Study: 7731301

Group type: EXPERIMENTAL
Intervention: xipamide
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 107
Study: 1835291

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide aerosol (36 micrograms)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Theophylline (dose titrated to produce serum levels of 10-20 micrograms/mL)
Number of subjects: 21
Study: 7304864

Group type: EXPERIMENTAL
Intervention: Epidural opiates
Number of subjects: 75
Study: 6737152

Group type: EXPERIMENTAL
Intervention: Preterm formula (PF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pooled pasteurized human milk (HM)
Number of subjects: 0
Study: 31957479

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 96
Study: 29265837

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 64
Study: 27657477

Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D/PTH(1-84) ratio
Number of subjects: 1237
Study: 24728028

Group type: EXPERIMENTAL
Intervention: Interferential current therapy (IFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TENS therapy
Number of subjects: 0
Study: 24509145

Group type: EXPERIMENTAL
Intervention: Open technique with free eruption (group 1, n=22)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Closed flap technique (group 2, n=21)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Quadrant of impacted canines
Number of subjects: 43
Study: 20642524

Group type: EXPERIMENTAL
Intervention: Flexiblade
Number of subjects: 32

Group type: COMPARATOR
Intervention: Macintosh
Number of subjects: 32
Study: 18560462

Group type: EXPERIMENTAL
Intervention: Tecnis Z9001 IOL
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sensar AR40e IOL
Number of subjects: 72
Study: 16603634

Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg intravenously at weeks 0 and 4
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Daclizumab 2 mg/kg intravenously at weeks 0, 2, 4, and 6
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 14604452

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 32
Study: 10891989

Group type: EXPERIMENTAL
Intervention: Rostral medial tegmental lesions
Number of subjects: 6

Group type: COMPARATOR
Intervention: Pontine base lesions
Number of subjects: 6
Study: 10423634

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 60 microg infused over 2 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1546144

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Moclobemide 200 mg b.i.d.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 3896811

Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg I.V. followed by oral administration)
Number of subjects: 800